Considerations on discontinuing natalizumab for the treatment of multiple sclerosis

Ann Neurol. 2010 Sep;68(3):409-11. doi: 10.1002/ana.22083.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized
  • Humans
  • Multiple Sclerosis / drug therapy*
  • Natalizumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Natalizumab